David M. O’Malley

31.3k total citations · 6 hit papers
454 papers, 11.8k citations indexed

About

David M. O’Malley is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, David M. O’Malley has authored 454 papers receiving a total of 11.8k indexed citations (citations by other indexed papers that have themselves been cited), including 253 papers in Reproductive Medicine, 180 papers in Oncology and 113 papers in Obstetrics and Gynecology. Recurrent topics in David M. O’Malley's work include Ovarian cancer diagnosis and treatment (243 papers), Endometrial and Cervical Cancer Treatments (108 papers) and PARP inhibition in cancer therapy (78 papers). David M. O’Malley is often cited by papers focused on Ovarian cancer diagnosis and treatment (243 papers), Endometrial and Cervical Cancer Treatments (108 papers) and PARP inhibition in cancer therapy (78 papers). David M. O’Malley collaborates with scholars based in United States, Spain and Canada. David M. O’Malley's co-authors include Ronald R. Sederoff, Ross Whetten, David E. Cohn, Kathleen N. Moore, David L. Remington, Ursula A. Matulonis, Jeffrey M. Fowler, Christophe Plomion, Floor Backes and Michael J. Birrer and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

David M. O’Malley

434 papers receiving 11.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

2017 406 citations Robert L. Coleman, Thomas J. Herzog et al. profile →
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

2019 289 citations David G. Mutch, David M. O’Malley et al. profile →
Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

2022 273 citations David M. O’Malley, Linda Mileshkin et al. Journal of Clinical Oncology profile →
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

2016 250 citations Michael J. Birrer, David M. O’Malley et al. profile →
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance

2023 110 citations Debra L. Richardson, Ramez N. Eskander et al. profile →
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

2023 81 citations Lucy Gilbert, Ana Oaknin et al. Gynecologic Oncology profile →

Peers

Countries citing papers authored by David M. O’Malley

Since Specialization

Citations

This map shows the geographic impact of David M. O’Malley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. O’Malley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. O’Malley more than expected).

Fields of papers citing papers by David M. O’Malley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. O’Malley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. O’Malley. The network helps show where David M. O’Malley may publish in the future.

Co-authorship network of co-authors of David M. O’Malley

This figure shows the co-authorship network connecting the top 25 collaborators of David M. O’Malley. A scholar is included among the top collaborators of David M. O’Malley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. O’Malley. David M. O’Malley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	69O Novel regimens for persistent/recurrent rare epithelial ovarian carcinomas (EOCs) selected according to biomarker status: ENGOT-GYN2/GOG-3051/BOUQUET phase II study results 2025 ·ESMO Open ·(unknown), Robert F. Miller, Jubilee Brown, JW Kim, (unknown), Andrés Redondo, Lauren E. Yauch, Max Dieterich, (unknown), Venkatesh Krishnan, Sana Intidhar Labidi‐Galy, Fatih Köse, Sandro Pignata, Lucy Gilbert, (unknown), Charlie Gourley, David M. O’Malley, June‐Yong Lee, Dominique Berton-Rigaud, David M. Gershenson	0
2	The GOG Foundation and EVA/LACOG partnership: a collaborative strategic alliance for clinical trial execution 2025 ·International Journal of Gynecological Cancer ·Fernando Cotait Maluf, Robert L. Coleman, Angélica Nogueira‐Rodrigues, Bradley J. Monk, Glauco Baiocchi, Kathleen N. Moore, Andréia Cristina de Melo, David M. O’Malley, Graziela Zibetti Dal Molin, Leslie M. Randall, Gonzalo Giornelli, Brian M. Slomovitz, René Pareja, Bhavana Pothuri, Ramez N. Eskander, Gustavo Werutsky, Thomas J. Herzog	0
3	A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer 2024 ·Gynecologic Oncology ·Eugenia Girda, Vicky Makker, Christian Marth, Toon Van Gorp, Mansoor Raza Mirza, (unknown), (unknown), Roman Groisberg, Fan Jin, David M. O’Malley	1
4	Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer. 2024 ·Journal of Clinical Oncology ·David M. O’Malley, Bradley Monk, Myong Cheol Lim, José Fuentes Pradera, Joseph Buscema, Michelle Wilson, Rocco De Vivo, Thomas J. Herzog, Flora Zagouri, Amit M. Oza, (unknown), John P. Diaz, Alla Lisyanskaya, Robert Morris, Ilan Bruchim, Marcia Craib, (unknown), Danny Shih, Keiichi Fujiwara, Rebecca Kristeleit	4
5	Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer 2024 ·Journal of Gynecologic Oncology ·Alexander Olawaiye, Jae‐Weon Kim, (unknown), Erin Bishop, Anita Chudecka-Głaz, (unknown), Laurence Gladieff, Mary E. Gordinier, Jacob Korach, Michael McCollum, Linda Mileshkin, Bradley J. Monk, Shibani Nicum, Angélica Nogueira‐Rodrigues, Ana Oaknin, David M. O’Malley, Mauro Orlando, Lyndah Dreiling, Iulia Cristina Tudor, Domenica Lorusso	4
6	A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer. 2024 ·Journal of Clinical Oncology ·(unknown), Sara Bouberhan, Konstantinos Papadimitriou, Rebecca C. Arend, (unknown), Roisin E. O’Cearbhaill, David M. O’Malley, Benoît You, Antonio González-Martı́n, Judith Michels, Linda Mileshkin, Yeh Chen Lee, (unknown), Suk‐Young Yoo, (unknown), (unknown), David A. Knorr, Israel Lowy, Thomas S. Uldrick, Elizabeth Miller	7
7	795TiP A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors 2024 ·Annals of Oncology ·Isabelle Laure Ray-Coquard, (unknown), David M. O’Malley, Ana Oaknin, Bhavana Pothuri, Domenica Lorusso, Ramez N. Eskander, Shannon N. Westin, (unknown), (unknown), (unknown), (unknown), Myong Cheol Lim, (unknown), José Alejandro Pérez Fidalgo, G. Curigliano, Mario Campone, Brian J. Sharkey, (unknown), Claire F. Friedman	1
8	Tissue factor as a novel diagnostic target for early detection of ovarian cancer using ultrasound microbubbles 2023 ·Gynecologic Oncology ·(unknown), Kalpana Deepa Priya Dorayappan, (unknown), Adrian A. Suarez, (unknown), (unknown), G. Larry Maxwell, David M. O’Malley, David E. Cohn, Michael F. Tweedle, Karuppaiyah Selvendiran	0
9	TP020/#1513 First-in-human phase 1/2 study of ubamatamab, a MUC16XCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer 2023 ·Lirias (KU Leuven) ·Kathleen N. Moore, Sara Bouberhan, Erika Hamilton, Joyce Liu, Roisin E. O’Cearbhaill, David M. O’Malley, Konstantinos Papadimitriou, (unknown), Els Van Nieuwenhuysen, Suk‐Young Yoo, Bin Wang, (unknown), Priscila Gonçalves, (unknown), Min Zhu, Israel Lowy, Thomas S. Uldrick, Elizabeth Miller	3
10	Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer 2023 ·International Journal of Gynecological Cancer ·Giorgio Bogani, Robert L. Coleman, Ignace Vergote, Toon Van Gorp, Isabelle Ray‐Coquard, Ana Oaknin, Ursula A. Matulonis, David M. O’Malley, Francesco Raspagliesi, Giovanni Scambia, Bradley J. Monk	26
11	2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma 2022 ·International Journal of Gynecological Cancer ·Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Léary, Robert W. Holloway, Margarita Amenedo, Peter C.C. Fong, Jeffrey C. Goh, David M. O’Malley, Sandra Goble, Lara Maloney, Jonathan A. Ledermann	16
12	2022-RA-439-ESGO Up-next (ENGOT-Ov71-NSGO-CTU/GOG-3049): a study of upitifamab rilsodotin (UpRi), a napi2b-directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer 2022 ·International Journal of Gynecological Cancer ·Mansoor Raza Mirza, David M. O’Malley, Philipp Harter, Thomas J. Herzog, Antonio González-Martı́n, (unknown), Robert A. Burger, Debra L. Richardson	1
13	2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine 2022 ·International Journal of Gynecological Cancer ·Ana Oaknin, Domenica Lorusso, Amit M. Oza, Nicoletta Colombo, Toon Van Gorp, David M. O’Malley, Susana Banerjee, Conleth G. Murphy, Philipp Harter, Gottfried E. Konecny, Marie‐Christine Kaminsky, Michael Method, Jiuzhou Wang, Robert L. Coleman, Michael J. Birrer, Ursula A. Matulonis, Kathleen N. Moore	1
14	A Rare Case of Atypical Placental Site Nodule With an Emerging Intermediate Trophoblastic Tumor 2019 ·International Journal of Gynecological Pathology ·(unknown), Wei Chen, David M. O’Malley, Brigitte M. Ronnett	7
15	Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center 2018 ·Gynecologic Oncology ·Adam C. ElNaggar, Erinn M. Hade, David M. O’Malley, Margaret Liang, Larry J. Copeland, Jeffrey M. Fowler, Ritu Salani, Floor Backes, David E. Cohn	12
16	A Prospective, Comparative Study for the Evaluation of Postoperative Pain and Quality of Recovery in Patients Undergoing Robotic Versus Open Hysterectomy for Staging of Endometrial Cancer 2016 ·Journal of Minimally Invasive Gynecology ·David E. Cohn, (unknown), Laura Huffman, Ritu Salani, Jeffrey M. Fowler, Larry J. Copeland, David M. O’Malley, Floor Backes, Eric Eisenhauer, Mahmoud Abdel‐Rasoul, Erika Puente-Poushnejad, Sergio D. Bergese	18
17	Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer 2016 ·Obstetrical & Gynecological Survey ·Katharine M. Esselen, Angel M. Cronin, Kristin Bixel, Michael A. Bookman, Robert A. Burger, David E. Cohn, Mihaela Cristea, Jennifer J. Griggs, Charles F. Levenback, Gina Mantia-Smaldone, Larissa A. Meyer, Ursula A. Matulonis, Joyce C. Niland, Charlotte C. Sun, David M. O’Malley, Alexi A. Wright	13
18	Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer 2015 ·Obstetrical & Gynecological Survey ·Alexi A. Wright, Angel M. Cronin, Dana Milne, Michael A. Bookman, Robert A. Burger, David E. Cohn, Mihaela Cristea, Jennifer J. Griggs, Nancy L. Keating, Charles F. Levenback, Gina Mantia-Smaldone, Ursula A. Matulonis, Larissa A. Meyer, Joyce C. Niland, Jane C. Weeks, David M. O’Malley	5
19	Uterine Serous Carcinoma: Increased Familial Risk for Lynch-Associated Malignancies 2012 ·Cancer Prevention Research ·Summer Dewdney, Nora T. Kizer, Abegail A. Andaya, (unknown), Jingqin Luo, David G. Mutch, Amy P. Schmidt, Louise A. Brinton, Russell R. Broaddus, Nilsa C. Ramirez, Phyllis C. Huettner, D. Scott McMeekin, Kathleen M. Darcy, Shamshad Ali, Patricia L. Judson, Robert S. Mannel, Shashikant B. Lele, David M. O’Malley, Paul J. Goodfellow	17
20	Enzyme variations in natural populations of Douglas-fir, Pseudotsuga menziesii (Mirb.) Franco, from British Columbia. 1. Genetic variation patterns in coastal populations. 1980 ·Silvae genetica ·Francis C. Yeh, David M. O’Malley	120

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact